ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted four newly-hired non-executive employees stock options to purchase an aggregate of 2,475 shares of the Company's common stock. The options were granted as of December 8, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $7.70 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as to 25% of the total amount of the award on the one-year anniversary of the vesting commencement date of December 2, 2024 and in thirty-six substantially equal monthly installments thereafter, subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options are subject to the terms and conditions of LENSAR's 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR's advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reducing overhead. ALLY includes LENSAR's proprietary Streamline software technology, which is designed to guide surgeons to achieve better outcomes.
| Contacts: | | Lee Roth / Cameron Radinovic |
| Thomas R. Staab, II, CFO | | Burns McClellan for LENSAR |
| ir.contact@lensar.com | | lroth@burnsmc.com / cradinovic@burnsmc.com |
佛罗里达州奥兰多，2024年12月9日（环球新闻网络）-- LENSAR公司（纳斯达克：LNSR）（"LENSAR"或"公司"）今天宣布，LENSAR董事会的大多数独立成员向四名新聘非执行员工授予了总计购买2,475股公司普通股的期权。这些期权自2024年12月8日起授予，作为每位员工入职公司的重要诱因。这些期权的授予符合纳斯达克上市规则5635(c)(4)。
这些期权的行使价为每股7.70美元，与授予日公司普通股的收盘价相等。期权根据2024年12月2日的归属开始日期的周年纪念日归属25%的总奖励金额，之后每月分36期等额归属，前提是新员工与公司的持续服务。每个股票期权的有效期为10年。期权受LENSAR 2024年就业诱因奖励计划的条款和条件以及涵盖授予的股票期权协议的约束。
关于LENSAR
LENSAR是一家商业阶段的器械公司，专注于设计、开发和营销用于治疗白内障和管理散光的卓越自动系统，将其作为手术的一个重要方面。LENSAR开发了其ALLY机器人白内障激光系统，作为一个紧凑型、高度人性化的系统，利用极其快速的双模态激光，并将人工智能集成到专有成像和软件中。ALLY旨在通过利用LENSAR的先进机器人技术来转变高端白内障手术，能够在无菌手术室或办公室手术室内进行整个手术，提供操作效率并降低开销。ALLY包括LENSAR的专有Streamline软件科技，旨在指导外科医生获得更好的治疗效果。
| 联系方式： | | 李·罗斯 / 卡梅伦·拉迪诺维奇 |
| 托马斯·R·斯塔布二世，首席财务官 | | 巴恩斯·麦克莱伦为LENSAR |
| ir.contact@lensar.com | | lroth@burnsmc.com / cradinovic@burnsmc.com |
